{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:59:17Z","timestamp":1785416357073,"version":"3.56.0"},"reference-count":60,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.3892\/ijmm.2017.2853","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T08:36:12Z","timestamp":1484123772000},"page":"268-278","source":"Crossref","is-referenced-by-count":18,"title":["Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis"],"prefix":"10.3892","volume":"39","author":[{"given":"Yuze","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangwei","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"key20180107234956_b1-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"key20180107234956_b2-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"key20180107234956_b3-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun"},{"key":"key20180107234956_b4-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1212\/WNL.0000000000000804","article-title":"Increased risk of osteoporosis in patients with myasthenia gravis: A population-based cohort study","volume":"83","author":"Yeh","year":"2014","journal-title":"Neurology"},{"key":"key20180107234956_b5-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10875-012-9834-5","article-title":"MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1","volume":"33","author":"Cheng","year":"2013","journal-title":"J Clin Immunol"},{"key":"key20180107234956_b6-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neulet.2013.09.014","article-title":"Altered expression of miR-146a in myasthenia gravis","volume":"555","author":"Lu","year":"2013","journal-title":"Neurosci Lett"},{"key":"key20180107234956_b7-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10238-015-0358-1","article-title":"Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis","volume":"16","author":"Zhang","year":"2016","journal-title":"Clin Exp Med"},{"key":"key20180107234956_b8-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: Rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107234956_b9-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/cei.12265","article-title":"Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis","volume":"176","author":"Wang","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"key20180107234956_b10-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107234956_b11-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"e6536","DOI":"10.1371\/journal.pone.0006536","article-title":"Human disease-drug network based on genomic expression profiles","volume":"4","author":"Hu","year":"2009","journal-title":"PLoS One"},{"key":"key20180107234956_b12-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"20131057","DOI":"10.1098\/rsif.2013.1057","article-title":"Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease","volume":"11","author":"Meng","year":"2013","journal-title":"J R Soc Interface"},{"key":"key20180107234956_b13-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s11434-012-4982-9","article-title":"A pathway profile-based method for drug repositioning","volume":"57","author":"Ye","year":"2012","journal-title":"Chin Sci Bull"},{"key":"key20180107234956_b14-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3988\/jcn.2011.7.4.173","article-title":"Treatment of myasthenia gravis based on its immunopathogenesis","volume":"7","author":"Kim","year":"2011","journal-title":"J Clin Neurol"},{"key":"key20180107234956_b15-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jns.2013.06.018","article-title":"Myasthenia gravis: New therapeutic approaches based on pathophysiology","volume":"333","author":"Lewis","year":"2013","journal-title":"J Neurol Sci"},{"key":"key20180107234956_b16-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"e104827","DOI":"10.1371\/journal.pone.0104827","article-title":"Identifying a polymorphic 'switch' that influences miRNAs' regulation of a myasthenia gravis risk pathway","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One"},{"key":"key20180107234956_b17-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ng0504-431","article-title":"The genetic association database","volume":"36","author":"Becker","year":"2004","journal-title":"Nat Genet"},{"key":"key20180107234956_b18-ijmm-39-02-0268","first-page":"bav028","article-title":"DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes","volume-title":"Database (Oxford)","author":"Pi\u00f1ero","year":"2015"},{"key":"key20180107234956_b19-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/514346","article-title":"Mendelian inheritance in man and its online version, OMIM","volume":"80","author":"McKusick","year":"2007","journal-title":"Am J Hum Genet"},{"key":"key20180107234956_b20-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"D940","DOI":"10.1093\/nar\/gkr972","article-title":"Disease Ontology: A backbone for disease semantic integration","volume":"40","author":"Schriml","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"key20180107234956_b21-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"D1070","DOI":"10.1093\/nar\/gkt1023","article-title":"HMDD v2.0: A database for experimentally supported human microRNA and disease associations","volume":"42","author":"Li","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"key20180107234956_b22-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/gb-2010-11-1-r6","article-title":"PhenomiR: A knowledgebase for microRNA expression in diseases and biological processes","volume":"11","author":"Ruepp","year":"2010","journal-title":"Genome Biol"},{"key":"key20180107234956_b23-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jbi.2011.05.002","article-title":"miRWalk - database: Prediction of possible miRNA binding sites by 'walking' the genes of three genomes","volume":"44","author":"Dweep","year":"2011","journal-title":"J Biomed Inform"},{"key":"key20180107234956_b24-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"D78","DOI":"10.1093\/nar\/gkt1266","article-title":"miRTarBase update 2014: An information resource for experimentally validated miRNA-target interactions","volume":"42","author":"Hsu","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"key20180107234956_b25-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"D98","DOI":"10.1093\/nar\/gkn714","article-title":"miR2Disease: A manually curated database for microRNA deregulation in human disease","volume":"37","author":"Jiang","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"key20180107234956_b26-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"D105","DOI":"10.1093\/nar\/gkn851","article-title":"miRecords: An integrated resource for microRNA-target interactions","volume":"37","author":"Xiao","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"key20180107234956_b27-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2105-11-135","article-title":"miRSel: Automated extraction of associations between microRNAs and genes from the biomedical literature","volume":"11","author":"Naeem","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"key20180107234956_b28-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"D1091","DOI":"10.1093\/nar\/gkt1068","article-title":"DrugBank 4.0: Shedding new light on drug metabolism","volume":"42","author":"Law","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"key20180107234956_b29-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/gb-2003-4-5-p3","article-title":"DAVID: Database for Annotation, Visualization, and Integrated Discovery","volume":"4","author":"Dennis","year":"2003","journal-title":"Genome Biol"},{"key":"key20180107234956_b30-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/bioinformatics\/btq675","article-title":"Cytoscape 2.8: New features for data integration and network visualization","volume":"27","author":"Smoot","year":"2011","journal-title":"Bioinformatics"},{"key":"key20180107234956_b31-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.clgc.2014.02.002","article-title":"Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib","volume":"12","author":"Jebb","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"key20180107234956_b32-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1042\/BST0361211","article-title":"Role of miRNA-146a in the regulation of the innate immune response and cancer","volume":"36","author":"Williams","year":"2008","journal-title":"Biochem Soc Trans"},{"key":"key20180107234956_b33-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imm.12347","article-title":"Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis","volume":"144","author":"Zhang","year":"2015","journal-title":"Immunology"},{"key":"key20180107234956_b34-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2169\/internalmedicine.32.519","article-title":"Expression of c-myc, c-Ki-ras and c-Ha-ras oncogene products in peripheral blood mononuclear cells from patients with myasthenia gravis","volume":"32","author":"Arimori","year":"1993","journal-title":"Intern Med"},{"key":"key20180107234956_b35-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0079-6603(01)67029-6","article-title":"Searching new targets for anticancer drug design: The families of Ras and Rho GTPases and their effectors","volume":"67","author":"Aznar","year":"2001","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"key20180107234956_b36-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J Immunol"},{"key":"key20180107234956_b37-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"key20180107234956_b38-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/CND.0b013e3181df2b3e","article-title":"Rituximab in the treatment of MuSK antibody-positive myasthenia gravis","volume":"12","author":"Stein","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"key20180107234956_b39-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol"},{"key":"key20180107234956_b40-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20180107234956_b41-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"key20180107234956_b42-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jns.2011.05.038","article-title":"Multiple paraneoplastic syndromes: Myasthenia gravis, vitiligo, alopecia areata, and oral lichen planus associated with thymoma","volume":"308","author":"Qiao","year":"2011","journal-title":"J Neurol Sci"},{"key":"key20180107234956_b43-ijmm-39-02-0268","article-title":"CARE-MS I and II Investigators: Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis","author":"Arroyo Gonz\u00e1lez","year":"2016","journal-title":"Mult Scler"},{"key":"key20180107234956_b44-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1212\/WNL.0000000000003319","article-title":"Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients","volume":"87","author":"Giovannoni","year":"2016","journal-title":"Neurology"},{"key":"key20180107234956_b45-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/art.23122","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes","volume":"58","author":"Lorenzi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20180107234956_b46-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4103\/0019-5154.143574","article-title":"Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer","volume":"59","author":"Datta-Mitra","year":"2014","journal-title":"Indian J Dermatol"},{"key":"key20180107234956_b47-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1111\/j.1365-2230.2008.02991.x","article-title":"Complete remission of psoriasis following bevacizumab therapy for colon cancer","volume":"34","author":"Akman","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"key20180107234956_b48-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/NEN.0b013e3182724831","article-title":"Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses","volume":"71","author":"MacMillan","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"key20180107234956_b49-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/RHU.0b013e3181c8e176","article-title":"Cetuximab in the treatment of rheumatoid arthritis","volume":"16","author":"Sullivan","year":"2010","journal-title":"J Clin Rheumatol"},{"key":"key20180107234956_b50-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1524-4741.2010.00953.x","article-title":"Trastuzumab in primary inflammatory breast cancer (IBC): High pathological response rates and improved outcome","volume":"16","author":"Dawood","year":"2010","journal-title":"Breast J"},{"key":"key20180107234956_b51-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1753-5174.2009.00026.x","article-title":"Efficacy and safety of efalizumab in patients with moderate-to-severe plaque psoriasis resistant to previous anti-psoriatic treatment: Results of a multicentre, open-label, phase IIIb\/IV trial","volume":"3","author":"Lotti","year":"2010","journal-title":"Arch Drug Inf"},{"key":"key20180107234956_b52-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1007\/s10620-010-1525-6","article-title":"Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's disease: an open-label pilot study","volume":"56","author":"James","year":"2011","journal-title":"Dig Dis Sci"},{"key":"key20180107234956_b53-ijmm-39-02-0268","article-title":"Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100U\/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials","author":"Polonsky","year":"2016","journal-title":"J Diabetes Complications"},{"key":"key20180107234956_b54-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2741\/4181","article-title":"Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin","volume":"18","author":"Cowan","year":"2013","journal-title":"Front Biosci (Landmark Ed)"},{"key":"key20180107234956_b55-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1365-2036.2006.02904.x","article-title":"Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease","volume":"23","author":"Creed","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"key20180107234956_b56-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1203\/00006450-200003000-00011","article-title":"A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways","volume":"47","author":"Piedimonte","year":"2000","journal-title":"Pediatr Res"},{"key":"key20180107234956_b57-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00534-010-0288-y","article-title":"Muromonab-CD3 therapy for refractory rejections after liver transplantation: a single-center experience during two decades in Japan","volume":"17","author":"Ueda","year":"2010","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"Suppl 4","key":"key20180107234956_b58-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ahj.2003.09.003","article-title":"Inflammation as a therapeutic target: a unique role for abciximab","volume":"146","author":"Kereiakes","year":"2003","journal-title":"Am Heart J"},{"key":"key20180107234956_b59-ijmm-39-02-0268","article-title":"Initial experience with tositumomab and I-131-labeled tositumomab for treatment of relapsed\/refractory Hodgkin lymphoma","author":"Jacene","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"key20180107234956_b60-ijmm-39-02-0268","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000368291","article-title":"Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant","volume":"133","author":"Arnason","year":"2015","journal-title":"Acta Haematol"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijmm.2017.2853\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T00:26:54Z","timestamp":1515371214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2017.2853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,1,11]]},"published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.3892\/ijmm.2017.2853"],"URL":"https:\/\/doi.org\/10.3892\/ijmm.2017.2853","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]}}}